Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect?

18Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bisphosphonates are recommended in the treatment of osteoporosis and some cancers, in which case they prevent the appearance of bone metastasis. The patients taking bisphosphonates are at increased risk of developing bisphosphonate-related osteonecrosis of jaw (BRONJ) which is characterised by the presence of an un-healing wound after dental surgery. BRONJ might represent an anti-angiogenic side effect. However, the real number of patients with BRONJ might be higher than currently recorded. Considering the differential diagnosis which includes various primary and secondary cancers, a correct histopathological diagnosis is very important. The morphological criteria for diagnosis of BRONJ are highlighted in this material.Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1813972972323288. © 2012 Petcu et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Petcu, E. B., Ivanovski, S., Wright, R. G., Slevin, M., Miroiu, R. I., & Brinzaniuc, K. (2012, July 6). Bisphosphonate-related osteonecrosis of jaw (BRONJ): an anti-angiogenic side-effect? Diagnostic Pathology. https://doi.org/10.1186/1746-1596-7-78

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free